Literature DB >> 11101629

A new monoclonal anti-CD3epsilon antibody reactive on paraffin sections.

L Alibaud1, R Llobera, T Al Saati, M March, G Delsol, B Rubin.   

Abstract

We generated a new monoclonal antibody (MAb), F7.2.38, by immunizing mice with CD3varepsilongammadelta/CD3omega complexes purified from human T-cells by OKT3 MAb-Sepharose affinity chromatography. Immunoprecipitation experiments and Western blotting analysis showed that MAb F7.2.38 recognized the CD3varepsilon chain in CD3varepsilon cDNA-transfected FOX B-cells and in various T-cell lines. Using flow cytometry on permeabilized or intact cells, the epitope was found to be located in the cytoplasmic tail of the CD3varepsilon chain. Immunohistochemical staining on paraffin-embedded sections showed that the reactivity of MAb F7.2.38 was comparable to that of the commercially available anti-CD3varepsilon polyclonal antibody. Of the 52 well-characterized T-cell lymphomas, 41 were positive for F7. 2.38 (79%), whereas all 37 B-cell lymphomas and 69 non-lymphoid tumors were unreactive. This new anti-CD3varepsilon antibody would be particularly useful for phenotyping T-cell lymphomas on routinely processed paraffin-embedded tissue sections.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11101629     DOI: 10.1177/002215540004801204

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  2 in total

1.  Evidence for early infection of nonneoplastic natural killer cells by Epstein-Barr virus.

Authors:  Pascal Trempat; Julie Tabiasco; Pascale Andre; Nathalie Faumont; Fabienne Meggetto; Georges Delsol; Randy D Gascoyne; Jean-Jacques Fournie; Eric Vivier; Pierre Brousset
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Myofibroblast activation in colorectal cancer lymph node metastases.

Authors:  T M Yeung; C Buskens; L M Wang; N J Mortensen; W F Bodmer
Journal:  Br J Cancer       Date:  2013-05-07       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.